Shearman & Sterling has advised Ethical Oncology Science (EOS) on its collaboration and license agreement with Servier to further develop EOS’s antitumor drug E-3810. Under the terms of this agreement, EOS will receive a €45 million upfront payment, and Servier will obtain an exclusive license, covering the world with the exception of the United States, Japan and China. In addition, for an undisclosed amount, EOS will receive clinical and registration milestones as well as royalties.

EOS S.p.A. is a biopharmaceutical company headquartered in Milan, Italy, developing novel targeted medicines to treat cancer. EOS is a privately held organization financed by founders and by Sofinnova Partners, AESCAP Venture and Principia SGR.

Servier is a privately-run French research-based pharmaceutical company. Current therapeutic domains for Servier medicines are cardiovascular, metabolic, neurological, psychiatric and bone and joint diseases, as well as oncology. Servier is established in 140 countries worldwide with over 20,000 employees and a 2011 turnover of €3.9 billion.

The Shearman & Sterling team included partners Michael Kennedy (San Francisco-Mergers & Acquisitions) and Richard Hsu (Palo Alto-Intellectual Property Transactions) and associate Lisa Lopshire (San Francisco-Mergers & Acquisitions).


Related Posts:

Leave a Reply